Original Contributions |
From the Departments of Pathology (M.D.R., C.W.W., D.G.), Internal Medicine (R.D.S., G.J.N., E.G.N.), and Physiology (E.G.N.), and Howard Hughes Medical Institute (G.J.N.), University of Michigan, Ann Arbor.
Correspondence to David Gordon, MD, Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research Division, 2800 Plymouth Rd, Ann Arbor, MI 48105. E-mail gordond{at}aa.wl.com
| Abstract |
|---|
|
|
|---|
100%), intimal smooth muscle
cells (1.3±0.4%, 1.4±1.0%, and 3.8±0.8% in the internal mammary
arteries, saphenous veins, and normal coronary arteries,
respectively), and various adventitial cells. Advanced, complicated
atherosclerotic plaques demonstrated a similar efficiency of
recombinant gene expression (3.1±0.5% and 3.8±0.3% of
nonendothelial intimal cells in the coronary
artery and carotid artery plaques, respectively). Of these intimal
cells, macrophages and smooth muscle cells expressed a
transgene, identifying them as targets for gene transfer. Areas of
plaque rupture and thrombus are sites of predilection for expression of
recombinant genes. Collagenase and elastase treatment
increased the percentage of transgenic alkaline phosphatasepositive
cells 7 times (P<0.001), suggesting that the pattern of
gene expression was affected by the amount of surrounding extracellular
matrix. These studies demonstrate the feasibility of gene transfer to
human blood vessels. However, these studies also highlight important
barriers to adenoviral gene delivery to the actual normal and
atherosclerotic human vessels of clinical interest.
Key Words: gene transfer smooth muscle cell macrophage arteriosclerosis human
| Introduction |
|---|
|
|
|---|
We introduced an adenovirus vector (ADV-hpAP) encoding a marker gene human placental alkaline phosphatase (hpAP) into normal and atherosclerotic human arteries and veins. Vessels were then maintained in organ culture, followed by histochemical staining for alkaline phosphatase. The goals of the study were to determine the following: (1) Can significant gene transfer be achieved with normal human blood vessels? (2) Is there a difference between normal and atherosclerotic vessels in susceptibility to a gene transfer? (3) What cell types can be readily infected in normal versus atherosclerotic vessels? (4) Do anatomic barriers (eg, extracellular matrix) influence the percentage of transgene-expressing cells in atherosclerotic plaques? These investigations were conducted to determine the feasibility of gene transfer into human blood vessels. Particular vessels were chosen because potential clinical targets of human gene therapy include normal coronary arteries of the donor heart to inhibit formation of transplant atherosclerosis or transplant rejection; normal saphenous veins and internal mammary arteries to inhibit coronary bypass graft intimal hyperplasia; advanced atherosclerotic plaques to stabilize and promote regression of occlusive inoperable atherosclerosis; and advanced, mechanically injured atherosclerotic plaques to prevent restenosis after the angioplasty. Although we described the overall patterns of transgene expression in human blood vessels, the main emphasis of this study was put on the transfectability of nonendothelial intimal cells (specifically, SMCs and macrophages) as the most probable direct participants of pathological intimal growth and therefore attractive targets for gene therapy.
| Materials and Methods |
|---|
|
|
|---|
E1, was used for control experiments. The second ADV,
ADV-hpAP, encodes for an hpAP reporter gene driven by a ß-actin
promoter and cytomegalovirus enhancer with an SV40 polyadenylation
sequence. Viral stocks were sterilized with a 0.45-µm filter and
evaluated for the presence of replication-competent virus as previously
described.7 10 None of the stocks used in these
experiments yielded replication-competent virus. Viral stocks were
diluted to titers of 1x1010 pfu/mL, stored at
-20°C, and thawed on ice for 5 minutes before use.
Tissue Collection
Rabbit Aortas
Thoracic aortas were obtained from intact New Zealand White
rabbits fed a regular chow. At euthanasia, aortic segments were
immediately immersed in M199 with 1% penicillin and streptomycin and
10% FCS. After rinsing, these segments were cut into rings 3 to 4
mm thick. Aortic rings were then transferred into 24-well plastic
dishes (1 ring per well) and maintained in the same culture medium.
Human Blood Vessels
Samples of normal and atherosclerotic human coronary
arteries were obtained from diseased hearts removed at the time of
heart transplantation. These hearts fell into two categories: (1)
idiopathic dilated cardiomyopathy, in which the
arteries display only normal diffuse intimal thickening with occasional
small atherosclerotic plaques, and (2) severe end-stage
coronary artery disease with myocardial infarctions in which
hemodynamically significant coronary
atherosclerosis is found. We also studied samples of
carotid artery plaques removed at the time of
endarterectomy surgery, because these frequently
display many advanced features of interest, such as thrombus
organization. Portions of internal mammary artery and saphenous vein
left over from coronary bypass surgery were obtained as an
example of normal human blood vessels. The final study set consisted of
14 coronary arteries (6 plaques and 8 normal arteries with
diffuse intimal thickening obtained from 5 hearts), 15 carotid plaques,
5 internal mammary arteries, and 4 saphenous veins. Vessels were cut
into rings 3 to 4 mm thick and handled as described above for
rabbit aortas. Time between surgical removal of the tissues and
beginning of gene transfer experiments did not exceed 2 hours. These
studies were approved by the Human Subjects Review Committee at the
University of Michigan.
Gene Transfer in Organ Culture
Rabbit Aorta
In our pilot experiments with the rabbit aortic rings, the
specimens were incubated with various dilutions of ADV-hpAP or
ADV-
E1 (2x105, 2x106,
2x107, 2x108,
2x109, and 2x1010 pfu/mL)
in DMEM containing 10% FCS, 1% glutamine, and 1%
penicillin-streptomycin for 30 minutes and 1, 3, 6, 12, and 24 hours at
37°C. After incubation with adenovirus, the specimens were washed in
M199, then maintained in M199 with 10% FCS, 1% glutamine, and 1%
penicillin-streptomycin for 2 days, and finally fixed in 10% formalin
overnight. It was determined (see "Results") that incubation of
rabbit aorta with adenovirus at a concentration
2x109 pfu/mL for 3 hours allowed the maximal
efficiency of transgene expression. Therefore, this protocol was used
for the experiments with human blood vessels.
Human Vessels
Rings of human vessels (3 to 5 per vessel) were incubated with
ADV-hpAP at a concentration of 2x109 pfu/mL for
3 hours, maintained in M199 with 10% FCS for 2 days, and fixed in 10%
formalin overnight. A set of carotid plaque samples (n=5) was fixed in
methacarn (methanol:chloroform:glacial acetic acid in a 60:30:10 volume
ratio) immediately after incubation with ADVs.
Enzymatically Digested Human Carotid Plaques
To evaluate the importance of extracellular connective tissue
matrix as a determinant of gene transfer efficiency into human
atherosclerotic lesions, 6 carotid plaques were gently
deendothelialized with a cotton swab and minced
into small pieces (10 to 20 pieces per plaque) of
3x3x3 mm.
Half of these pieces were treated with a mixture of 0.15%
collagenase, type 4 (isolated from Clostridium
histolyticum, 213 U/mg dry wt, obtained from Worthington) and
0.01% pancreatic elastase (90 U/mg dry wt, obtained from Sigma)
dissolved in M199 for 1 hour at 37°C.11 No
manipulations to remove other enzymatic activities (eg, addition of
specific enzyme inhibitors) were performed. The other half
was incubated in M199 under the same conditions and was used as a
control. After the enzymatic treatment, minced tissue was washed in
M199, incubated with ADV-hpAP, maintained in organ culture, and fixed
in 10% formalin overnight. A separate set of carotid plaques (n=5) was
subjected to the same procedure but was fixed in methacarn immediately
after incubation with adenovirus.
Tissue Processing
Fixed specimens were dehydrated and embedded in paraffin. All
samples from the same blood vessel were placed into one block. Thus,
each tissue block contained several (minimum, 3) pieces from the same
vessel.
Histochemistry
Expression of recombinant hpAP protein was detected by
histochemical analysis of infected, formalin-fixed vascular
samples. The slides were deparaffinized and incubated in PBS at 65°C
for 30 minutes to inactivate endogenous
alkaline phosphatase. The sections were incubated in PBS containing a
chromogenic substrate of 5-bromo-4-chloro-3-indolyl
phosphate-p-toluidine (1 mg/mL, Gibco BRL) and nitro blue
tetrazolium chloride (1 mg/mL, Gibco BRL) for 19 hours. This substrate
yields a dark purple-to-brown stain in the presence of alkaline
phosphatase. Pellets of 293 cells infected with either ADV-hpAP or
ADV-
E1, fixed in formalin, and processed in the same fashion as the
organ culture samples were used as positive and negative tissue
controls, respectively.
Immunocytochemistry
Single-Label Immunocytochemistry
Carotid plaque sections fixed in methacarn immediately
after the incubation with ADV-hpAP were used for immunocytochemical
analysis of the tissue distribution of adenoviral particles
(immediate results of adenoviral infection). Sections were
deparaffinized, and goat anti-adenovirus (anti-hexon) antibody
(dilution 1:100, Biodesign) was applied overnight at 4°C. The
secondary antibody incubation (biotinylated horse anti-goat antibody,
1:200 dilution, Vector Laboratories) was for 30 minutes at room
temperature, followed by streptavidinalkaline phosphatase (dilution
1:1000, Vector Laboratories) for 30 minutes, then developed with
alkaline phosphatase substrate (alkaline phosphatase substrate kit I,
Vector Laboratories), which produced a red reaction product.
Adenovirus-positive and -negative control slides were obtained from
Chemicon International, Inc.
Combination of Alkaline Phosphatase Histochemistry and
Immunocytochemistry
Recombinant hpAP activity may localize separately or together
with the immunocytochemical signal of interest. We used slightly
different techniques for analysis of these two distinct types
of spatial associations. (1) Staining of separate tissue structures: To
address the question about spatial relationships between local
transgene expression and organized thrombi in advanced carotid
atherosclerotic plaques, we combined alkaline phosphatase histochemical
staining with fibrin II immunostaining, which was used
as a marker of thrombus/hemorrhage-related fibrin
deposition.12 Mouse antifibrin II ß-chain
antibody NYB-T2G112 was supplied by Accurate
Chemical and Scientific Corp. Alkaline phosphatase staining was carried
out as described above. The primary antibody (NYB-T2G1 at 1:50 dilution
in 2% normal horse serum) was applied overnight at 4°C. The
biotinylated horse anti-mouse antibody (dilution 1:200) was then
applied for 3 hours at 4°C, followed by another 30-minute incubation
in streptavidinalkaline phosphatase (dilution 1:1000, Vector
Laboratories) for 30 minutes, then developed with alkaline phosphatase,
which produced a red reaction product. (2) Staining of colocalized
structures: To identify the cell types expressing the transgene hpAP,
combined alkaline phosphatase histochemistry and cell typespecific
immunocytochemistry was performed. The cell typespecific antibodies
used on these tissues were as follows: a monoclonal mouse
-actin
antibody (1:500 dilution, Boehringer Mannheim Biochemical) to
identify SMCs, a monoclonal mouse CD68 antibody (1:1000 dilution, DAKO)
to identify monocyte/macrophages, and goat polyclonal antivon
Willebrandt factor antibody (1:200 dilution, Atlantic
Antibodies) to identify endothelial cells. All primary
antibodies were diluted with 2% normal horse serum. The biotinylated
secondary antibody was then applied for 3 hours at 4°C, followed by
streptavidincolloidal gold (1:1000 dilution, Goldmark Biologicals)
for 30 minutes. Slides were then incubated with the silver enhancement
kit (Goldmark Biologicals) for 10 to 15 minutes under microscopic
control.
In Situ Hybridization Assay of Cell Viability
Rationale
Although various techniques are available for accurate
evaluation of cell viability in tissue culture on a cell-by-cell
basis,13 we are not aware of any reliable
approach applicable to intact tissue in situ or in organ culture. We
assume that translational activity may serve as an approximate index of
cell viability (in other words, dead cells are not expected to make
mRNA and synthesize proteins). Therefore, we proposed to use in situ
detection of polyadenylated mRNA sequences as a marker of
viable cells within the tissue. Polyadenylated mRNA sequences
are conserved in routine paraffin-embedded specimens and can be readily
demonstrated with labeled poly d(T) probes.14
This technique was applied to specimens before they were placed into
the organ culture to evaluate tissue preservation, as well as after
adenoviral infection and in specimens maintained in organ culture, to
assess cell viability after these potentially injurious
manipulations.
Methodology and Validation
In situ hybridization with the fluorescein-labeled
poly d(T) oligonucleotide was performed using the probe
and detection kit provided by Novocastra Laboratories. The slides were
incubated with proteinase K in 0.05 mol/L Tris/HCl buffer (pH 7.6) for
30 minutes at 37°C, then were hybridized with
oligonucleotide probe during 2 hours at 37°C.
Detection of the hybridized probe included incubation with
anti-fluorescein rabbit antibody conjugated to alkaline
phosphatase (1:100 dilution in TBS) for 30 minutes and, finally,
incubation in alkaline phosphatasedeveloping solution, as described
above for alkaline phosphatase histochemical staining. As a control for
specificity of in situ hybridization, serial sections were incubated
with fluorescein-labeled random
oligonucleotide cocktail provided by Novocastra
Laboratories. To validate this novel assay of cell viability, cultured
rat aortic SMCs were killed by incubation with 0.1% saponin for 10
minutes,15 which was confirmed by conventional
cell viability assay (Life/Death kit, Molecular Probes), washed with
PBS, and fixed 1, 2, and 4 hours later. Poly d(T) in situ assay
revealed that virtually all untreated cells were poly Apositive.
Notably, strong nuclear and cytoplasmic staining was found. In 1 hour,
cytoplasmic staining completely disappeared, whereas
80% of the
nuclei exhibited faint signal. Two and 4 hours after treatment, only
20% of the nuclei were very weakly stained, whereas the rest of the
cells were totally negative. Therefore, we concluded that mRNA loss is
a fairly early indicator of cell death and therefore may be used to
evaluate cell viability in organ culture.
Evaluation of Tissue Integrity
Advanced, complicated plaques often have complex geometry,
determined by surface erosions and ruptures.16 We
hypothesized that cells adjacent to such "openings" may have better
accessibility to adenoviral particles and therefore a greater degree of
the transgene expression. To label original contours of the plaques, we
used the Davidson Marking System (Bradley
Products).17 Carotid plaque rings were
incubated with ADV-hpAP and maintained in organ culture for 2 days.
Before formalin fixation, they were incubated with green tissue-marking
dye for 5 minutes. After histochemical staining for alkaline
phosphatase, spatial associations among the cells expressing a
transgenic hpAP (purple cytoplasm) and bright green marks of the plaque
openings were assayed.
Morphometric Analysis
Sections were studied by light microscopy with the Image 1
system of image analysis (Universal Imaging Corp).
Nonoverlapping microscopic fields covering the whole section were
analyzed. On the single-labeled slides, each field was scored
for total number of nuclei and number of hpAP-positive cells. The
average index per sample was then used to calculate the statistical
comparisons between different normal and atherosclerotic blood vessels.
With the double-labeled slides, the percentage of hpAP-positive cells
that were associated with each cell typespecific marker was
determined, with averages again computed on a per-sample basis. Average
percentages of hpAP-positive cells for each group of blood vessels were
obtained and compared either by Student's t test or one-way
ANOVA. Statistical analysis was performed with the statistical
package Epistat (Epistat Services).
| Results |
|---|
|
|
|---|
|
After experimenting with various concentrations of adenovirus
(2x105, 2x106,
2x107, 2x108,
2x109, and 2x1010 pfu/mL)
and dwell time (30 minutes and 1, 3, 6, 12, and 24 hours), we concluded
that incubation of rabbit aorta with adenovirus at a concentration of
2x109 pfu/mL for 3 hours allowed the maximal
efficiency of transgene expression (Figures 1c
, 1d
, and 2
). No toxic effects were observed in the
range of vector concentrations used. Alkaline phosphatase histochemical
staining revealed that all endothelial cells and
various number of adventitial cells expressed a transgene. No medial
SMCs showed alkaline phosphatase positivity. No alkaline phosphatase
staining was observed in the mock-transfected specimens. Thus, rabbit
experiments demonstrated the feasibility of the organ culture approach
to evaluation of a transgene expression in vascular tissues.
|
Normal Human Blood Vessels
A difference between rabbit aorta and normal human vessels is the
presence of distinct subendothelial intima (Figure 3a
). It consists of several layers of
SMCs and extracellular matrix. The number of
subendothelial cells varies in different human vessels
(from 1 to 3 layers in the internal mammary arteries to 5 to 10 layers
in the coronary arteries). In situ hybridization assay
demonstrated very good preservation of these cells in organ culture
conditions (Figure 3b
). The patterns of transgene expression were very
similar in all types of normal human vessels. Typically, hpAP was
expressed by luminal endothelial cells and scattered
subendothelial cells (Figure 3c
and 3e
). Despite
100% of luminal endothelial cells being
hpAP-positive (when optimal vector concentration was used), <5% of
subendothelial cells expressed the transgene (Figure 4
), and expression was typically found
adjacent to endothelium. However, this pattern was
reproducibly altered at the sites near the side branches, where several
layers of intimal cells exhibited hpAP positivity (Figure 3d
).
Combination of alkaline phosphatase histochemical staining and
cell-specific immunogold labeling demonstrated that the vast majority
of hpAP-expressing subendothelial cells were also
-actin positive (Figure 3f
, Table
). There were no
statistically significant differences in the overall numbers of
hpAP-positive intimal cells among normal human blood vessels (Figure 4
). We also did not find any difference in adventitial expression of
hpAP, which spanned from 10% to 21% in different preparations.
|
|
|
Human Atherosclerotic Plaques
Atherosclerotic plaques typically consist of a lipid/necrotic core
and an overlying fibrous cap that isolates this core from the
arterial lumen (Figure 5a
).
In this study, coronary plaques were usually less advanced,
whereas carotid plaques frequently displayed erosions,
hemorrhages, and organized thrombi. Both morphological
analysis and in situ hybridization assay demonstrated excellent
tissue preservation of human atherosclerotic plaque explants (Figure 5a
and 5b
).
|
The pattern of a transgene expression in atherosclerotic plaques was
very similar to that in normal arteries; transgenic hpAP was expressed
by almost all luminal endothelial and scattered
subendothelial cells (Figure 5c
). Clusters of
hpAP-positive intimal cells were occasionally seen at sites of
artificial endothelial desquamation (data not shown).
However, the absence of endothelium was not a
sufficient predictor of increased transgene expression by the intimal
cells. At the same time, numerous hpAP-positive cells were associated
with the sites of plaque erosions and organized thrombi (Figure 5d
).
This association was confirmed by use of the combination of alkaline
phosphatase histochemical staining and fibrin immunocytochemistry
(Figure 5e
). Despite such differences in the localization of the
transgene-expressing cells, statistical analysis did not reveal
significant differences between the overall numbers of hpAP-positive
intimal (nonendothelial) cells in human plaques versus
normal blood vessels (Figure 4
). Eight percent to 20% of the
adventitial cells expressed hpAP, which also did not differ from normal
vessels.
As described above in normal vessels, hpAP expression was observed in
SMCs (Figure 5f
). In contrast to the pattern of expression observed in
normal vessels, hpAP expression was also seen in macrophages
(Figure 5g
). Foamy macrophages, a hallmark of
atherosclerosis, also often expressed hpAP (Figure 5h
).
Of all hpAP-positive plaque intimal cells, 30% to 60% were SMCs, 25%
to 50% were macrophages, and up to 20% did not express either
of those cell typespecific markers (Table
).
Plaque Integrity and Efficiency of Gene Transfer
We hypothesized that the pattern and efficiency of transgene
expression was affected by the physical accessibility of the plaque
cells to the vector. To test this hypothesis, we labeled original
contours (and therefore the openings) of the plaques with a dye. It was
evident that hpAP-expressing cells, regardless of the cell type, were
localized within the labeled (open) regions on both luminal and
abluminal sides of the carotid plaques (Figure 6a
and 6b
). This pattern corroborated the
pattern of distribution of adenoviral particles immediately after
infection (Figure 6c
).
|
To address the question about the role of extracellular matrix as an
anatomic barrier for adenovirus penetration, we gently
deendothelialized carotid plaques, minced them
into small pieces, treated them with a mixture of
collagenase and elastase, and transfected the tissue.
Comparison of relative areas occupied by
hexon-immunostainable material immediately after infection
revealed that enzymatic pretreatment increased the area containing
hexon staining 6 times (P<0.01) (Figures 6d
, 6e
, and 7
). Accordingly, 2 days after
transfection, a 7-fold increase in the percentage of alkaline
phosphatasepositive cells was observed in digested versus untreated
plaques (P<0.001) (Figures 6f
, 6g
, and 8
). Thus, not only did more efficient
gene transfer correlate with the natural plaque openings, but
artificial exposure of plaque cells further increased the number of
transgene-expressing cells.
|
|
| Discussion |
|---|
|
|
|---|
Our results showed that almost all luminal endothelial cells and a variable number of adventitial cells within the explants of normal human coronary arteries, internal mammary arteries, and saphenous veins express recombinant genes after adenoviral infection. This pattern was very similar to findings observed in organ culture of rabbit aorta and to previous studies of in vivo transfection of normal animal arteries.1 21 Interestingly, up to 5% of subendothelial smooth musclelike cells also actively expressed a transgene. This observation is important because these cells are the most likely source of intimal growth in atherosclerosis, restenosis, and bypass graft intimal hyperplasia.22 23 Moreover, in our experiments, subendothelial transduction was greater at branch points. The exact nature of this phenomenon is unknown. However, it may be determined by increased endothelial permeability24 and/or different architecture of subendothelial extracellular matrix, resulting in the better access of ADVs to subendothelial smooth musclelike cells. Thus, the ability to target intimal cells without intentional endothelial denudation in organ culture conditions suggests the feasibility of gene therapy for human transplant arteriosclerosis and bypass graft failure.
The organ culture approach is attractive for analysis of gene transfer into human atherosclerotic plaques, because certain advanced features of human lesions, such as plaque ruptures, erosions, and hemorrhages, are difficult to reproduce in the animal models. At the same time, advanced, complicated plaques may be the most appealing target for human gene therapy. We demonstrated that the overall efficiency of recombinant gene expression in nonendothelial intimal cells in human plaques is similar to that of their normal counterparts. However, cells adjacent to the loci of plaque rupture and cells associated with organized thrombi were more prone to gene transfer. Unfortunately, we were unable to analyze potential relationships between the type of lesion and efficiency of gene transfer, because fresh human tissues with early atherosclerotic lesions like fatty streaks were not available for this study.
It is difficult to compare our results with the data obtained in animal
experiments in vivo, because gene transfer has always been combined
with some sort of mechanical injury of the preexisting atherosclerotic
plaques.10 25 26 In other words, there are no
data describing the patterns of transgene expression in intact animal
atherosclerotic lesions. Previous studies using
percutaneous delivery of ADVs encoding a
lacZ reporter gene in atherosclerotic rabbit arteries with a
channel balloon demonstrated transgene expression in
0.2% of
intimal and medial cells. This result was
10-fold lower than
observed in balloon-injured normal arteries.25
Recently, when delivering ADV-hpAP to atherosclerotic rabbit arteries
after surgical exposure of arteries, we demonstrated that
32% of
intimal and medial cells in balloon-injured atherosclerotic lesions
expressed a transgene.10 In other studies, no
differences in luciferase activity were observed between
atherosclerotic balloon-injured and normal porcine coronary
arteries after percutaneous delivery of ADVs encoding a
luciferase gene with a porous balloon catheter.26
It is likely that such variability reflects the problems of
catheter-based gene delivery. Organ culture experiments do not have
this limiting step. Recent data of Ooboshi et
al20 demonstrate that adenovirus-mediated gene
transfer to the endothelium was much more effective in
atherosclerotic than in normal monkey and rabbit arteries in organ
culture.
It has also been reported that lacZ gene transfer into
balloon-injured rabbit atherosclerotic arteries resulted in a transgene
expression exclusively by SMCs.25 In our hands,
however, a combination of histochemical alkaline phosphatase staining
and immunogold cell typespecific labeling of human plaques in organ
culture revealed hpAP gene expression in luminal
endothelial cells, SMCs, and
monocyte/macrophages. Moreover,
20% of the
transgene-expressing cells did not express any of the above cell
typespecific markers. These results corroborate our recent
observations of different cell types expressing a transgene in rabbit
atherosclerotic lesions.10 Thus, our data suggest
a broad scope of cellular targets for gene therapy of human
atherosclerosis.
There appeared to be no cell type in human atherosclerotic plaques that is intrinsically resistant to adenovirus-mediated gene transfer. We have also demonstrated that the vast majority of plaque cells are viable in organ culture. However, not every viable cell expressed a transgene. Our results showed that adenoviral particles immediately after infection, as well as transgene-expressing cells (regardless of the cell type) 2 days after infection, tended to localize next to the plaque openings, such as erosions, ruptures, organized mural thrombi, etc. Taken together, these data imply the presence of permeability barriers, which limit adenoviral particles from reaching their cellular targets, otherwise potentially transfectable. The presence of anatomic barriers determining the pattern and efficiency of transgene expression has been established in animal experiments.1 27 No such data are available for advanced human atherosclerotic lesions. Because endothelial preservation in the explants of human atherosclerotic plaques is likely to be suboptimal, we decided not to analyze the role of endothelium (although potentially important), but rather to test a specific hypothesis that in advanced human atherosclerotic plaques, dense fibrous matrix serves as a barrier for adenovirus-mediated gene transfer. Carotid plaques were gently deendothelialized, minced, treated with a mixture of collagenase and elastase, then infected with ADV-hpAP and maintained in organ culture. Our results show that the efficiency of vector penetration was increased 6-fold, and accordingly, a number of transgene-expressing cells was increased 7-fold, compared with untreated plaque fragments. We suggest that the observed increase in the efficiency of transgene expression is caused primarily by barrier reduction, although the minor influence of extracellular matrixdependent alterations in gene expression cannot be completely ruled out. Thus, having demonstrated that the highest efficiency of gene transfer was associated with either natural (erosions, ruptures, etc) or artificial (enzymatic treatment) plaque openings, we concluded that the actual pattern of gene expression depends on the exposure of individual cells to adenoviral particles, and this is affected by the amount of surrounding extracellular matrix. Moreover, these results show that the most vulnerable sites of atherosclerotic plaques are more prone to gene transfer than the rest of the plaque. Such plaques may be an excellent target for gene therapy aimed at stabilization of vulnerable atherosclerotic plaques.28
Thus, we have demonstrated the feasibility of gene transfer into both normal and atherosclerotic human blood vessels. Characteristics of the efficiency and patterns of a transgene expression in human vessels should support future efforts to design gene therapy for arteriosclerosis, restenosis, and graft failure.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received December 2, 1997; accepted March 25, 1998.
| References |
|---|
|
|
|---|
2.
Guzman RJ, Lemarchand P, Crystal RG, Epstein SE,
Finkel T. Efficient and selective adenovirus-mediated gene transfer
into vascular neointima. Circulation. 1993;88:28382848.
3.
Steg PG, Feldman LJ, Scoazec JY, Tahlil O, Barry JJ,
Boulechfar S, Ragot T, Isner JM, Perricaudet M. Arterial
gene transfer to rabbit endothelial and smooth muscle
cells using percutaneous delivery of an adenoviral
vector. Circulation. 1994;90:16481656.
4. Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WR, Clowes AW. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest. 1994;93:644651.
5.
Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel
EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular
proliferative disorders with a constitutively active form of the
retinoblastoma gene product. Science. 1995;267:518522.
6.
Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS,
Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts
resistant to atherosclerosis. Proc Natl
Acad Sci U S A. 1995;92:45024506.
7.
Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ,
Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell
proliferation after arterial injury [see comments].
Science. 1994;265:781784.
8. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996;2:293298.[Medline] [Order article via Infotrieve]
9.
Lemarchand P, Jaffe HA, Danel C, Cid MC, Kleinman HK,
Stratford Perricaudet LD, Perricaudet M, Pavirani A, Lecocq JP, Crystal
RG. Adenovirus-mediated transfer of a recombinant human alpha
1-antitrypsin cDNA to human endothelial cells.
Proc Natl Acad Sci U S A. 1992;89:64826486.
10. Simari RD, San H, Rekhter M, Ohno T, Gordon D, Nabel GJ, Nabel EG. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest. 1996;98:225235.[Medline] [Order article via Infotrieve]
11. Rekhter MD, Tertov VV, Andreeva ER, Kolpakov V, Mironov AA, Orekhov AN. Lipid accumulation in the subendothelial cells of human aortic intima impairs cell-to-cell contacts: a comparative study in situ and in vitro. Cardiovasc Pathol. 1993;2:5362.
12.
Bini A, Fenoglio JJ Jr, Mesa-Tejada R, Kudryk B, Kaplan
KL. Identification and distribution of fibrinogen, fibrin, and
fibrin(ogen) degradation products in
atherosclerosis: use of monoclonal antibodies.
Arteriosclerosis. 1989;9:109121.
13.
Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P.
Apoptosis of vascular smooth muscle cells induced by in vitro
stimulation with interferon-gamma, tumor necrosis factor-alpha, and
interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996;16:1927.
14. Pringle JH, Primrose L, Kind CN, Talbot IC, Lauder I. In situ hybridization demonstration of poly-adenylated RNA sequences in formalin-fixed paraffin sections using a biotinylated oligonucleotide poly d(T) probe. J Pathol. 1989;158:279286.[Medline] [Order article via Infotrieve]
15. Haugland RP. Assays for cell viability, proliferation, and function. In: Spence MTZ, ed. Handbook of Fluorescent Probes and Research Chemicals. 6th ed. Eugene, OR: Molecular Probes, Inc; 1996.
16. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques [see comments]. Lancet. 1989;2:941944.[Medline] [Order article via Infotrieve]
17. Parkinson AV, Cannon CR, Hayne ST. Color coding surgical margins with the Davidson marking system. J Histotechnol. 1990;13:293294.
18.
Ooboshi H, Chu Y, Rios CD, Faraci FM, Davidson BL,
Heistad DD. Altered vascular function after adenovirus-mediated
overexpression of endothelial nitric oxide synthase.
Am J Physiol. 1997;273:H265H270.
19. Takeshita S, Losordo DW, Kearney M, Rossow ST, Isner JM. Time course of recombinant protein secretion after liposome-mediated gene transfer in a rabbit arterial organ culture model. Lab Invest. 1994;71:387391.[Medline] [Order article via Infotrieve]
20.
Ooboshi H, Rios CD, Chu Y, Christenson SD, Faraci FM,
Davidson BL, Heistad DD. Augmented adenovirus-mediated gene transfer to
atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17:17861792.
21.
Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA.
Endothelium-specific in vivo gene transfer. Circ
Res. 1995;77:475485.
22.
Schwartz SM, deBlois D, O'Brien ER. The intima: soil
for atherosclerosis and restenosis. Circ
Res. 1995;77:445465.
23.
Stary HC, Blankenhorn DH, Chandler AB, Glagov S,
Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ,
Wagner WD, Wissler RW. A definition of the intima of human arteries and
of its atherosclerosis-prone regions: a report from the
Committee on Vascular Lesions of the Council on
Arteriosclerosis, American Heart Association.
Arterioscler Thromb. 1992;12:120134.
24. Bell FP, Adamson IL, Schwartz CJ. Aortic endothelial permeability to albumin: focal and regional patterns of uptake and transmural distribution of 131-I albumin in the young pig. Exp Mol Pathol. 1974;20:5768.[Medline] [Order article via Infotrieve]
25. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, Barry JJ, Dedieu JF, Perricaudet M, Isner JM. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit [see comments]. J Clin Invest. 1995;95:26622671.
26.
French BA, Mazur W, Ali NM, Geske RS, Finnigan JP,
Rodgers GP, Roberts R, Raizner AE. Percutaneous
transluminal in vivo gene transfer by recombinant adenovirus in normal
porcine coronary arteries, atherosclerotic arteries, and two
models of coronary restenosis. Circulation. 1994;90:24022413.
27.
Rome JJ, Shayani V, Flugelman MY, Newman KD, Farb A,
Virmani R, Dichek DA. Anatomic barriers influence the distribution of
in vivo gene transfer into the arterial wall: modeling with
microscopic tracer particles and verification with a recombinant
adenoviral vector. Arterioscler Thromb. 1994;14:148161.
28.
Lee RT, Libby P. The unstable atheroma.
Arterioscler Thromb Vasc Biol. 1997;17:18591867.
This article has been cited by other articles:
![]() |
T. Yamaoka, Y. Yonemitsu, K. Komori, H. Baba, T. Matsumoto, T. Onohara, and Y. Maehara Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1865 - H1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jiang, A. Mezentsev, R. Kemp, K. Byun, J. R. Falck, J. M. Miano, A. Nasjletti, N. G. Abraham, and M. Laniado-Schwartzman Smooth Muscle--Specific Expression of CYP4A1 Induces Endothelial Sprouting in Renal Arterial Microvessels Circ. Res., February 6, 2004; 94(2): 167 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Poller, H. Fechner, M. Noutsias, C. Tschoepe, M. Pauschinger, and H.-P. Schultheiss The molecular basis of cardiotropic viral infections Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I18 - I30. [Abstract] [PDF] |
||||
![]() |
B. Burke, S. Sumner, N. Maitland, and C. E. Lewis Macrophages in gene therapy: cellular delivery vehicles and in vivo targets J. Leukoc. Biol., September 1, 2002; 72(3): 417 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cavusoglu, I. Chen, J. Rappaport, and J. D. Marmur Inhibition of Tissue Factor Gene Induction and Activity Using a Hairpin Ribozyme Circulation, May 14, 2002; 105(19): 2282 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Scherpereel, J. J. Rome, R. Wiewrodt, S. C. Watkins, D. W. Harshaw, S. Alder, M. Christofidou-Solomidou, E. Haut, J.-C. Murciano, M. Nakada, et al. Platelet-Endothelial Cell Adhesion Molecule-1-Directed Immunotargeting to Cardiopulmonary Vasculature J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 777 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. CONDORELLI, J. K. AYCOCK, G. FRATI, and C. NAPOLI Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice FASEB J, October 1, 2001; 15(12): 2162 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chu, D. D. Heistad, M. I. Cybulsky, and B. L. Davidson Vascular Cell Adhesion Molecule-1 Augments Adenovirus-Mediated Gene Transfer Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 238 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-S. Bolz, S. Pieperhoff, C. De Wit, and U. Pohl Intact endothelial and smooth muscle function in small resistance arteries after 48 h in vessel culture Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H1434 - H1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens Gene therapy in the cardiovascular system: an update Cardiovasc Res, December 1, 1999; 44(3): 498 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. M. Campbell, M. A. Kuliszewski, and D. J. Stewart Cell-Based Gene Transfer to the Pulmonary Vasculature . Endothelial Nitric Oxide Synthase Overexpression Inhibits Monocrotaline-Induced Pulmonary Hypertension Am. J. Respir. Cell Mol. Biol., November 1, 1999; 21(5): 567 - 575. [Abstract] [Full Text] |
||||
![]() |
W. Erl, G. K. Hansson, R. de Martin, G. Draude, K. S. C. Weber, and C. Weber Nuclear Factor-{kappa}B Regulates Induction of Apoptosis and Inhibitor of Apoptosis Protein-1 Expression in Vascular Smooth Muscle Cells Circ. Res., April 2, 1999; 84(6): 668 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Morishita Lessons From Human Arteries : How to Design a Gene Therapy Strategy for Treatment of Cardiovascular Disease Circ. Res., June 29, 1998; 82(12): 1349 - 1351. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |